Toniv,
Yes it has been discussed. Empagliflozin = Jardiance. I've linked a few of my posts on it, as well as jogged your memory on a couple of yours!. The RRR for Jardiance for 3-point MACE (cardiovascuar death, non-fatal MI, non-fatal stroke) in EMPA-REG Outcomes was 14%. There was a neutral effect on MI and stroke and a 38% reduction in death for overal 14% RRR for 3-point MACE. Resverlogix is hoping for 25-30% RRR for this same 3-point MACE in BETonMACE
Jariance #1
Jardiance #2
Jardiance #3
Jardiance #4
And here are a couple of your own replies to that thread Toniv, here and here.
In regards to one of your concerns in those posts, I asked Sarah at Resverlogix whether hitting the 25-30% mark for RRR in BETonMACE was required for success even if they achieved a lower RRR with statistical significance, and she replied that it would still be a success. So any RRR that acheived a significant p-value will be a success. Though the value of the drug will be much higher with the greater RRR.
Best regards,
BearDownAZ
